Moderna Stock Falls After Goldman Downgrade. Vaccine Sales Are a Worry.
Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.
Moderna Stock Is Sliding Wednesday: Here's Why
Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...
pulmonologyadvisor2d
Moderna Receives $590M From HHS to Develop Bird Flu Vaccine
The US Department of HHS is awarding the pharmaceutical company Moderna $590 million to continue developing a vaccine to protect against bird flu.
Moderna Hold Recommendation Amid Reduced Revenue Projections and Price Target
In a report released today, Tyler Van Buren from TD Cowen maintained a Hold rating on Moderna (MRNA – Research Report), with a price target of ...
Moderna price target lowered to $50 from $60 at Evercore ISI
Evercore ISI lowered the firm’s price target on Moderna (MRNA) to $50 from $60 and keeps an In Line rating on the shares. The firm is updating ...
Yahoo Finance18d
Moderna target nearly halved by Morgan Stanley on weak guidance
Investing.com -- Morgan Stanley slashed its price target on Moderna Inc (BMV ... ongoing competitive pressures in the vaccine market. The firm noted Moderna's reduced 2024 sales forecast of ...
Decoding Moderna's Options Activity: What's the Big Picture?
Delving into the details, we found 51% of traders were bullish, while 25% showed bearish tendencies. Out of all the trades we ...
Moderna: Is Stock a Buy? Breaking Down the Latest Guidance
"We remain focused on our three strategic priorities: driving sales growth, delivering up to 10 product approvals over the ...
Yahoo Finance18d
Moderna price target drops, fintech Outperform, FDA hits tobacco
Moderna's (MRNA) price target slashed to $38 from $70 by Morgan ... Analysts cite lowered 2025 revenue outlook and vaccine market competition. Fintech leaders SoFi (SOFI) and Affirm (AFRM) have ...